Versant Capital Management
TARS icon

Versant Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Versant Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.73K Buy
22
+19
+633% +$1.32K ﹤0.01% 2626
2026
Q2 		$189 Hold
3
– – ﹤0.01% 2731
2026
Q1 		$210 Hold
3
– – ﹤0.01% 2756
2025
Q4 		$246 Hold
3
– – ﹤0.01% 2612
2025
Q3 		$178 Buy
+3
New +$148 ﹤0.01% 2610

Other funds holding TARS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Emerald Investment Advisers
Emerald Investment Advisers Leola, Pennsylvania $1.45B AUM

Versant Capital Management's TARS Position: Q3 2026 in Review

Versant Capital Management increased its Tarsus Pharmaceuticals (TARS) stake by 633% in Q3 2026, buying an estimated $1.32K and bringing the position to 22 shares worth $1.73K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Versant Capital Management first reported a position in TARS in Q3 2025 and has held it in 5 quarters since. 90 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • Versant Capital Management held 22 shares of Tarsus Pharmaceuticals worth $1.73K as of Q3 2026.
  • Versant Capital Management bought 19 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $1.32K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2626 holding.
  • Versant Capital Management first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 90 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.